Abstract
The South Korean economy has been growing over the past five decades at an average annual rate of 6.2 per cent. In 2011 gross domestic product (GDP) per capita was US$20,870 (World Bank, 2012). The rapid ageing of South Korea’s population, however, has sparked intense debate and recognition of the imperative to shift the focus of growth away from manufacturing to services, including welfare services. South Korea’s National Health Insurance (NHI), which covers 97 per cent of the population, and the Long-term Care Insurance System, introduced in 2008, will assist this transition to an ageing society.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Health Korea News (2010) ‘There is Something Special About Drugs Developed Using Improved Chemical Entities’ 26 August, http://www.hkn24.com/news/articleView.html?idxno=54333, date accessed 25 October 2011.
IMS Health (2010) ‘Pharmerging Shake-up: New Imperatives in a Redefined World’, http://www.imshealth.com/imshealth/Global/Content/IMS%20Institute/Documents/Pharmerging_Shakeup.pdf/imshealth/Global/Content/IMS%20Institute/Documents/Pharmerging_Shakeup.pdf, date accessed 9 August 2011.
Jung, C.-H. (2004) ‘Transition of Patent System in Korea: History of Strengthening Patent’, Journal of Science and Technology Policy 14(3), 79–107.
KFDA, see Korean Food and Drug Administration.
KHIDI, see Korean Health Industry Development Institute.
Korean Assembly Special Committee Report for KOR–US FTA (2007) Analysis of the Economic Impact of KOR–US FTA (Seoul: Republic of Korea).
Korean Food and Drug Administration (2007) Regulation on Evaluation of Drug Safety and Efficacy, no. 2007–20.
Korean Food and Drug Administration (2010) Food and Drug Statistical Year Book 2010 (Seoul: KFDA).
Korean Health Industry Development Institute (2007) Study on the Establishment of Pharmaceutical Industry Development Plan (Seoul: KHIDI).
Korean Health Industry Development Institute (2008) ‘A Development Plan for Cooperation between Foreign and Local Pharmaceutical Companies’, Health Industry Policy Issue Report 5 (Seoul: KHIDI).
Korean Health Industry Development Institute (2010) ‘Analysis on Pharmaceutical Industry’, http://el.khidi.or.kr/hermes/, date accessed 25 October 2011.
Korean Pharmaceutical Manufacturers’ Association (2010) Pharmaceutical Industry Statistics Report (Seoul: KPMA).
KPMA, see Korean Pharmaceutical Manufacturers’ Association.
Kwon, H.-Y. and B.-M. Yang (2010) ‘Issues with Orphan Drug Pricing in South Korea’, Korean Journal of Health Economics and Policy 16(2), 17–37.
Lee, Y.-J. (2007) ‘Striking a Balance between Patent Rights and Access to Medicines in Developing Countries: The TRIPS Agreement and Beyond’, Korean Journal of Industrial Property 24, 189–234.
Ministry of Health and Welfare (2010) Statistics for Health Insurance and Health Policy (Seoul: Ministry of Health and Welfare).
Nam, H.-S. (2006) ‘Pharmaceutical Monopoly System and KOR–US FTA Negotiations’, Health Insurance Forum 5(3), 15–27.
National Health Insurance Corporation (2011) NHI Statistical Year Book 2011 (Seoul: NHIC).
NHIC, see National Health Insurance Corporation.
OECD Health Data (2011) http://www.oecd.org/document/16/0,3746,en_2649_34631_2085200_1_1_1_1,00.html/document/16/0,3746,en_2649_34631_2085200_1_1_1_1,00.html, date accessed 2 January 2012.
Park, Y.-G. (2007) ‘Harmonizing and Prospect of the International Patent System’, Korean Journal of Industrial Property 24, 103–43.
World Bank (2012) ‘Data Republic of Korea’, http://data.worldbank.org/country/korea-republic/country/korea-republic, date accessed 1 December 2012.
Editor information
Editors and Affiliations
Copyright information
© 2013 Bong-min Yang and Hye-young Kwon
About this chapter
Cite this chapter
Yang, Bm., Kwon, Hy. (2013). TRIPS and New Challenges for the Pharmaceutical Sector in South Korea. In: Löfgren, H., Williams, O.D. (eds) The New Political Economy of Pharmaceuticals. International Political Economy Series. Palgrave Macmillan, London. https://doi.org/10.1057/9781137315854_11
Download citation
DOI: https://doi.org/10.1057/9781137315854_11
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-32976-2
Online ISBN: 978-1-137-31585-4
eBook Packages: Palgrave Social Sciences CollectionSocial Sciences (R0)